Bridgewest Group today announced the successful acquisition of Pfizer’s sterile injectable manufacturing facility in Perth, creating a world-class manufacturing hub for LumaCina and reinforcing Australia’s position in the global pharmaceutical supply chain.
The 34,000-square-metre site in Bentley employs over 400 staff and houses nine production lines, including high-potency, oncology, blow-fill-seal, and multi-format vial capabilities. With regulatory approvals from the FDA, TGA, and EMA, the facility exports medicines to more than 90 countries and is one of Australia’s most advanced sterile injectable plants.
“This facility is more than an acquisition – it is a strategic investment in Australia’s pharmaceutical independence,” said [Executive Name, Title, Bridgewest Perth Pharma]. “By integrating the site into the LumaCina platform, we are ensuring supply continuity, expanding global partnerships, and creating new opportunities for innovation.”
As part of the transition, Bridgewest will continue manufacturing existing Pfizer products under a master services agreement, safeguarding supply for patients worldwide. In parallel, the site will expand production for LumaCina’s pipeline and serve as a contract development and manufacturing organization (CDMO) to support biotech and pharma innovators.
The acquisition provides LumaCina with the scale and technical expertise to accelerate its sterile injectables business while contributing to Australia’s broader national strategy to strengthen domestic medicine manufacturing and reduce reliance on overseas supply chains.
